|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts receivable, net | ||||||||||||||||||||
| Royalty receivable | ||||||||||||||||||||
| Inventory, net | ||||||||||||||||||||
| Convertible loan receivable | ||||||||||||||||||||
| Prepaid and other assets | ||||||||||||||||||||
| Current assets related to discontinued operations (Note 3) | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term assets | ||||||||||||||||||||
| Net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Investment in equity securities | ||||||||||||||||||||
| Right of use assets – operating leases | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Long-term assets related to discontinued operations (Note 3) | ||||||||||||||||||||
| Total long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and shareholders’ equity | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Accrued bonuses and commissions | ||||||||||||||||||||
| Accrued royalties and expenses | ||||||||||||||||||||
| Earnout liabilities – current | ||||||||||||||||||||
| Current portion of debt | ||||||||||||||||||||
| Operating lease liabilities – current | ||||||||||||||||||||
| Current liabilities related to discontinued operations (Note 3) | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Earnout liabilities – long-term | ||||||||||||||||||||
| Operating lease liabilities – long-term | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Common Stock: $0.001 par value, 20,000,000 shares authorized; 9,193,394 issued and outstanding as of June 30, 2026 and 8,946,913 issued and outstanding as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Sanara MedTech shareholders’ equity | ||||||||||||||||||||
| Equity attributable to noncontrolling interest | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
